Actelion (XSWX:ATLNE) Price-to-Tangible-Book : 6.80 (As of May. 02, 2024)

View and export this data going back to . Start your Free Trial

What is Actelion Price-to-Tangible-Book?

As of today (2024-05-02), Actelion's share price is CHF65.26. Actelion's Tangible Book per Share of Mar. 2017 for the quarter that ended in Mar. 2017 was CHF9.60. Hence, Actelion's Price to Tangible Book Ratio of today is 6.80.

The historical rank and industry rank for Actelion's Price-to-Tangible-Book or its related term are showing as below:

XSWX:ATLNE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.98 Med: 7.63 Max: 28.15
Current: 26

During the past 13 years, Actelion's highest Price to Tangible Book Ratio was 28.15. The lowest was 2.98. And the median was 7.63.

XSWX:ATLNE's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.71 vs XSWX:ATLNE: 26.00

A closely related ratio is called PB Ratio. As of today, Actelion's share price is CHF65.26. Actelion's Book Value per Sharefor the quarter that ended in Mar. 2017 was CHF13.97. Hence, Actelion's P/B Ratio of today is 4.67.

Actelion Price-to-Tangible-Book Historical Data

The historical data trend for Actelion's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Price-to-Tangible-Book Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.12

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Actelion's Price-to-Tangible-Book

For the Biotechnology subindustry, Actelion's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actelion's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Actelion's Price-to-Tangible-Book falls into.

Actelion Price-to-Tangible-Book Calculation

Actelion's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2017 )
	=	65.26	/	9.599
	=	6.80

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Actelion Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Actelion's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (XSWX:ATLNE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (XSWX:ATLNE) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (XSWX:ATLNE) Headlines

No Headlines